<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-314
Date of Submission: 2024-12-04

This report was submitted by a Pharmacist from Vincent-Powers Medical Center concerning patient ANON-PX-1806. The subject is an adult female with a significant medical history including chronic kidney disease, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Intravenous route at a dosage of 33mg, initiated on 2024-10-31 for Hypothyroidism with the course ongoing.

On approximately 2024-11-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Somnolence, Anaphylaxis. The Stevens-Johnson syndrome was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Somnolence was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Anaphylaxis was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed determine and advised more. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Glass since security while simple cut. Each spring exactly. Figure law entire I operation.</data>
report_id: ADR-2024-314
report_date: '2024-12-04'
patient_details:
  patient_id: ANON-PX-1806
  gender: Female
  relevant_history:
  - chronic kidney disease
  - type 2 diabetes
suspected_drugs:
- drug_name: Levothyroxine
  dosage: 33mg
  route_of_administration: Intravenous
  start_date: '2024-10-31'
  indication_for_use: Hypothyroidism
  drug_class: Thyroid hormone
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2024-11-25'
  severity: Life-threatening
  outcome: Unknown
  intervention_required: true
- symptom_name: Somnolence
  onset_date: '2024-11-25'
  severity: Life-threatening
  outcome: Unknown
  intervention_required: false
- symptom_name: Anaphylaxis
  onset_date: '2024-11-25'
  severity: Life-threatening
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed determine and advised more.
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive dechallenge
reporting_facility: Vincent-Powers Medical Center
reporter_type: Pharmacist
notes: Glass since security while simple cut. Each spring exactly. Figure law entire
  I operation.
